Alan Colowick
Director/Board Member chez ACELYRIN, INC.
Fortune : 20 124 $ au 31/03/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
David J. Lockhart | M | 62 |
ReCode Therapeutics, Inc.
ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | - |
Shao Lee Lin | M | 57 | 5 ans | |
Carlos A. Schuler | M | - |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | 15 ans |
Christopher Hall | M | 55 | 2 ans | |
Bruce Cozadd | M | 60 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 15 ans |
Albert W. Gianchetti | M | 59 |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | - |
Peter Thompson | M | 64 |
ReCode Therapeutics, Inc.
ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | 9 ans |
Martin Babler | M | 59 |
Alumis, Inc.
Alumis, Inc. Pharmaceuticals: MajorHealth Technology Alumis, Inc. is a precision medicines company called Esker that aims to provide personalized treatments for people with autoimmune diseases. The company is based in San Francisco, CA. Esker uses a precision analytics platform, powered by foresite labs, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology to create medicines that change the lives of people with autoimmune disease. The company was founded by June H Lee. Martin Babler has been the CEO of the company since 2021. | 3 ans |
Karin Eastham | F | 74 | 5 ans | |
Dan Becker | M | 49 | 6 ans | |
Regina Salvat | M | - |
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | 4 ans |
Jennifer Augusti | F | - |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | - |
Stephen Moore | M | 52 | 4 ans | |
Todd K. Rosengart | M | - |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | 11 ans |
Ronald Crystal | M | - |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | 11 ans |
Olivia Bloom | F | 55 | 2 ans | |
Gil Labrucherie | M | 52 | 2 ans | |
David Reese | M | 61 | 19 ans | |
Karah Parschauer | F | 46 | 7 ans | |
Shehnaaz Suliman | M | 52 |
ReCode Therapeutics, Inc.
ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | 2 ans |
Leighanne Oh | F | - |
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | 5 ans |
Arthur Bowman | M | 77 | 5 ans | |
Matthew Busch | M | 50 | 20 ans | |
Robert Eckert | M | 69 | 21 ans | |
Jonathan Leff | M | 66 |
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | 10 ans |
Beth Seidenberg | M | 67 | 8 ans | |
Clarence Machado | M | 60 | 5 ans | |
Woodrow Myers | M | 70 | 3 ans | |
Mina Kim | F | 50 | 2 ans | |
Sapna R. Srivastava | M | 53 |
VelosBio, Inc.
VelosBio, Inc. Miscellaneous Commercial ServicesCommercial Services VelosBio, Inc. operates as an biopharmaceutical company. It developes antibody-drug conjugates to treat hematological cancers and solid tumors. The company was founded in 2017 and is headquartered in San Diego, CA.
Alumis, Inc.
Alumis, Inc. Pharmaceuticals: MajorHealth Technology Alumis, Inc. is a precision medicines company called Esker that aims to provide personalized treatments for people with autoimmune diseases. The company is based in San Francisco, CA. Esker uses a precision analytics platform, powered by foresite labs, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology to create medicines that change the lives of people with autoimmune disease. The company was founded by June H Lee. Martin Babler has been the CEO of the company since 2021. | 3 ans |
Lonnie Shoff | F | 65 | 2 ans | |
Daniel Welch | M | 66 |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA.
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | 9 ans |
Oleg Nodelman | M | 47 |
ReCode Therapeutics, Inc.
ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | - |
Vikram Bajaj | M | 46 |
Alumis, Inc.
Alumis, Inc. Pharmaceuticals: MajorHealth Technology Alumis, Inc. is a precision medicines company called Esker that aims to provide personalized treatments for people with autoimmune diseases. The company is based in San Francisco, CA. Esker uses a precision analytics platform, powered by foresite labs, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology to create medicines that change the lives of people with autoimmune disease. The company was founded by June H Lee. Martin Babler has been the CEO of the company since 2021. | - |
James Tananbaum | M | 60 |
Alumis, Inc.
Alumis, Inc. Pharmaceuticals: MajorHealth Technology Alumis, Inc. is a precision medicines company called Esker that aims to provide personalized treatments for people with autoimmune diseases. The company is based in San Francisco, CA. Esker uses a precision analytics platform, powered by foresite labs, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology to create medicines that change the lives of people with autoimmune disease. The company was founded by June H Lee. Martin Babler has been the CEO of the company since 2021. | - |
Rana Al-Hallaq | M | - |
ReCode Therapeutics, Inc.
ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | - |
Michael Rome | M | - |
Alumis, Inc.
Alumis, Inc. Pharmaceuticals: MajorHealth Technology Alumis, Inc. is a precision medicines company called Esker that aims to provide personalized treatments for people with autoimmune diseases. The company is based in San Francisco, CA. Esker uses a precision analytics platform, powered by foresite labs, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology to create medicines that change the lives of people with autoimmune disease. The company was founded by June H Lee. Martin Babler has been the CEO of the company since 2021. | - |
Nikhil Thatte | M | - |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | - |
A. Davis | M | 57 |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | - |
Peng Li | M | - |
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | 5 ans |
Chet Leach | M | - |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | - |
Ron Oyston | M | 54 | 2 ans | |
Luke Walker | M | - | 2 ans | |
Perry Nisen | M | 68 |
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | 6 ans |
Aaditya Sekar | M | - |
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | 4 ans |
Isaac Cheng | M | 49 |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | - |
Daniel Hetu | M | - |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | - |
Johan Rutger Christenson | M | 65 |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | - |
John Paul de Koning | M | 55 |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | - |
Glenn Batchelder | M | 63 |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | - |
Fouad Azzam | M | 57 |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | - |
Julian Baker | M | 57 |
Alumis, Inc.
Alumis, Inc. Pharmaceuticals: MajorHealth Technology Alumis, Inc. is a precision medicines company called Esker that aims to provide personalized treatments for people with autoimmune diseases. The company is based in San Francisco, CA. Esker uses a precision analytics platform, powered by foresite labs, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology to create medicines that change the lives of people with autoimmune disease. The company was founded by June H Lee. Martin Babler has been the CEO of the company since 2021. | - |
Lynn Tetrault | F | 61 | 1 ans | |
Debbie Murray | F | - |
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | 4 ans |
Helen Kim | F | 61 |
ReCode Therapeutics, Inc.
ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | 4 ans |
Louis Lange | M | 72 |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | - |
Aneal Tenjarla | M | - |
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | 5 ans |
R. Session | M | 45 |
ReCode Therapeutics, Inc.
ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | - |
Andrew ElBardissi | M | 42 |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | - |
Samantha Miller | F | 59 |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | - |
Luiz Belardinelli | M | - |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | 8 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Jacqualyn Fouse | M | 62 | 7 ans | |
Sol Barer | M | 76 | 25 ans | |
John West | M | 67 | 11 ans | |
Joel A. Fernandes | M | 54 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | - |
Thomas Daniel | M | 69 | 12 ans | |
Blake Wise | M | 53 | 4 ans | |
John Smither | M | 71 | 7 ans | |
Jonathan Biller | M | 61 | 8 ans | |
Kathryn Falberg | F | 63 | 6 ans | |
Stewart M. Kroll | M | 65 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 11 ans |
Gary Loeb | M | 54 | 3 ans | |
Jean Franchi | F | 57 | 2 ans | |
Annalisa Jenkins | M | 58 | 3 ans | |
David Johnson | M | 59 |
VelosBio, Inc.
VelosBio, Inc. Miscellaneous Commercial ServicesCommercial Services VelosBio, Inc. operates as an biopharmaceutical company. It developes antibody-drug conjugates to treat hematological cancers and solid tumors. The company was founded in 2017 and is headquartered in San Diego, CA. | 3 ans |
Grace E. Colón | M | 57 |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | 10 ans |
Suzanne Kim | F | - |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | 6 ans |
Timothy J. Smith | M | - | - | |
Michael Dybbs | M | 49 | 2 ans | |
Georgia Erbez | F | 57 | 4 ans | |
Gerald McMahon | M | 69 | 5 ans | |
Michael S. Ostrach | M | 72 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 1 ans |
Christopher Chai | M | 58 | 7 ans | |
Jonathan MacQuitty | M | 71 | 11 ans | |
Joanne Viney | M | 58 | 13 ans | |
Scott Rocklage | M | 69 | 11 ans | |
David W. Beier | M | 75 | 10 ans | |
Peter Kellogg | M | 67 | 5 ans | |
Michael Kelly | M | 67 | 14 ans | |
Brendan Delaney | M | 49 | 6 ans | |
Robert Lisicki | M | 57 |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | 1 ans |
Brian M. McNamee | M | 67 | - | |
Gerald F. Masoudi | M | 56 | 3 ans | |
Willard Dere | M | 70 | 11 ans | |
Sandy Mahatme | M | 59 | 6 ans | |
Arlene Morris | F | 72 | 3 ans | |
Andargachew Zelleke | M | 62 |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | 4 ans |
Fabio M. Benedetti | M | 58 | - | |
Rodman L. Drake | M | 80 | 8 ans | |
Ruben Gutierrez | M | 49 |
Human Longevity, Inc.
Human Longevity, Inc. BiotechnologyHealth Technology Human Longevity, Inc. provides precision health analytics to individuals through the Health Nucleus. The Health Nucleus is an assessment of current and future risk for cardiac, oncologic, metabolic and cognitive diseases and conditions. The firm offers database of sequenced genomes and phenotypic data. The company was founded by J. Craig Venter, Robert Joseph Hariri Gordon, and Peter H. Diamandis in 2013 and is headquartered in San Diego, CA. | 4 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 100 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Alan Colowick
- Réseau Personnel